EBS

Emergent BioSolutions Inc. - Q3 2008 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended September 30, 2008. Emergent BioSolutions Inc. is a biopharmaceutical company focused on developing, manufacturing, and commercializing immune-related biologics, primarily for biodefense (anthrax and botulinum) and commercial infectious diseases. The company's primary revenue driver is BioThrax, the only FDA-licensed anthrax vaccine, sold predominantly to the U.S. Department of Health and Human Services (HHS) and the Department of Defense (DoD).

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 30% year-over-year for the quarter ($56.6M vs. $43.6M) and 53% for the nine-month period ($142.8M vs. $93.3M). This was driven by a 33% increase in product sales revenue for the quarter, primarily due to a 34% increase in the average sales price per dose of BioThrax.
• Profitability: The company reported a net income of $10.4M for the quarter, compared to $2.8M in the prior year quarter. For the nine months ended September 30, 2008, the company reported a net income of $19.2M, a significant turnaround from a net loss of $4.8M in the same period in 2007.
• Operating Expenses: Research and Development (R&D) expenses increased 30% for the quarter ($16.6M vs. $12.8M) due to higher contract service costs and asset acquisitions (including a $1M milestone payment for a VaxGen vaccine candidate). Selling, General, and Administrative (SG&A) expenses decreased 6% for the quarter ($14.1M vs. $15.0M) due to reduced professional services.
• Segment Performance: The Biodefense segment generated net income of $26.3M for the quarter, while the Commercial segment incurred a net loss of $13.4M.

Guidance, Outlook, and Risks

• Contract Outlook: The company entered into a new agreement on September 30, 2008, with HHS to supply up to 14.5 million additional doses of BioThrax for the Strategic National Stockpile (SNS) through September 2011. The total purchase price is estimated between $362.7M and $402.8M, contingent on FDA approval of a four-year shelf-life extension.
• Manufacturing: The company is nearing completion of a new 50,000 sq. ft. manufacturing facility in Lansing, Michigan, with approximately $72M incurred to date. Qualification and validation activities are ongoing.
• Legal Contingencies:
  • Protein Sciences Corporation (PSC): Emergent is engaged in litigation with PSC regarding a $10M loan and a terminated asset purchase agreement. Emergent alleges fraud and breach of contract, seeking damages of at least $13M plus punitive damages. PSC claims a $1.5M break-up fee and disputes the immediate repayment of the loan.
  • Product Liability: While past BioThrax product liability lawsuits have been dismissed or resolved, the company notes ongoing risks related to the mandatory vaccination program and potential future litigation.
• Risk Factors: Key risks include dependence on U.S. government contracts, potential delays in FDA approvals for new facilities or product candidates, and the uncertainty of winning future competitive bids for biodefense contracts.

Investor Verification Checklist

• Government Contract Reliance: Verify the stability of HHS and DoD funding for BioThrax, as these entities represent the vast majority of revenue.
• Shelf-Life Extension: Monitor the status of the FDA application to extend BioThrax shelf-life from three to four years, as this triggers a price increase on future contracts.
• PSC Litigation Outcome: Assess the potential financial impact of the lawsuit against Protein Sciences Corporation, including the recoverability of the $10M note receivable.
• Manufacturing Capacity: Confirm the timeline for FDA qualification of the new Lansing facility to ensure it can meet future demand.
• Debt Covenants: Review the terms of the $58.4M debt outstanding, particularly covenants related to the revolving line of credit and term loans.